PTC Therapeutics Inc. Receives Positive Opinion from the CHMP; Prosensa Holding N.V. Climbs Higher after Positive Twitter Remark

Follow this company

Companies Mentioned

05/27/2014 [ACCESSWIRE]

PTC Therapeutics, Inc. (NASDAQ: PTCT) shares nearly doubled this past Friday after the company received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe for translarna, which is the branded name given to ataluren, the company's lead investigational compound. According to a press release, following its request for a reexamination of translarna as a treatment for nonsense mutation Duchenne muscular dystrophy, the CHMP recommended the conditional marketing authorization of the compound. This recommendation will be taken into consideration by the European Medicines Agency on whether to grant EU market approval over the coming months.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Its lead product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutations or nmCF.

Get more information on PTC Therapeutics, Inc. and free access to the in depth equity report at: wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at to get full access to our free stock reports.

Prosensa Holding N.V. (NASDAQ: RNA) shares climbed higher this past Friday after the CHMP gave a positive opinion to Ataluren from PTC Therapeutics. Following the news, TheStreet's Adam Feuerstein stated on Twitter that Prosensa (RNA) "has to be a lock approval for exon 51 DMD in EU."

Prosensa Holding N.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. The company’s products focus on the treatment of neuromuscular and neurodegenerative disorders, including duchenne muscular dystrophy (DMD), myotonic dystrophy, and huntington’s diseases.

Get more information on Prosensa Holding N.V. and free access to the in depth equity report at” 


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.


Leave a comment...

Your Name